|
291 Companies |
|
371 Products |
|
371 Products |
|
177 Mechanisms of Action |
|
18 Trials |
|
3694 News |
|
| 12345678910111213...7778» |
- ||| sunitinib / Generic mfg.
Trial completion: OCCLURANDOM: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (clinicaltrials.gov) - Apr 20, 2025
P2, N=84, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Recruiting --> Completed
- | Yervoy (ipilimumab) / BMS
Phase classification, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Jan 24, 2024
P1, N=3, Terminated, Sponsor: Stanford University
Recruiting --> Completed Phase classification: P1/2 --> P1
- | Trial completion, Phase classification, Enrollment change: Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 (clinicaltrials.gov) - Jan 12, 2024
P1, N=27, Completed, Sponsor: Stanford University
Phase classification: P1/2 --> P1 Suspended --> Completed | Phase classification: PN/A --> P1 | N=46 --> 27
- | Enrollment change, Trial withdrawal: Clinical and Pathologic Studies in Neuroendocrine Tumors (clinicaltrials.gov) - Nov 28, 2023
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Suspended --> Completed | Phase classification: PN/A --> P1 | N=46 --> 27 N=200 --> 0 | Terminated --> Withdrawn
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Phase classification, Combination therapy, Gene therapy: Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma (clinicaltrials.gov) - Nov 21, 2023
P2, N=52, Completed, Sponsor: Candel Therapeutics, Inc.
N=200 --> 0 | Terminated --> Withdrawn Phase classification: P2a --> P2
- | citicoline / Generic mfg.
Trial completion, Enrollment change: Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy (clinicaltrials.gov) - Nov 13, 2023
P=N/A, N=21, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Phase classification: P2a --> P2 Active, not recruiting --> Completed | N=80 --> 21
- | NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: Minitub: Minimal SN Tumor Burden (clinicaltrials.gov) - Oct 6, 2023
P=N/A, N=296, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed | N=80 --> 21 Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Dec 2031 | Trial primary completion date: Jul 2023 --> Dec 2023
- ||| TVI-Brain-1 / TVAX Biomedical
Enrollment change: Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma (clinicaltrials.gov) - Jun 29, 2023
P2, N=14, Completed, Sponsor: TVAX Biomedical
Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Dec 2031 | Trial primary completion date: Jul 2023 --> Dec 2023 N=86 --> 14
- | AU-105 / Aurora Biopharma
Trial completion: HERT-GBM: CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (clinicaltrials.gov) - Apr 25, 2019
P1, N=16, Completed, Sponsor: Baylor College of Medicine
N=86 --> 14 Active, not recruiting --> Completed
- | Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change, Trial termination: Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Apr 23, 2019
P1, N=15, Terminated, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed N=23 --> 15 | Active, not recruiting --> Terminated; Insufficient accrual
- ||| Enrollment change, Surgery: Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery (clinicaltrials.gov) - Apr 20, 2019
P2, N=72, Completed, Sponsor: Matthew R Quigley
N=23 --> 15 | Active, not recruiting --> Terminated; Insufficient accrual N=150 --> 72
- | Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma (clinicaltrials.gov) - Apr 20, 2019
P1, N=31, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=150 --> 72 Active, not recruiting --> Completed
- || Signifor LAR (pasireotide long acting release) / Recordati
Trial completion, Trial completion date, Trial primary completion date: Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) - Apr 20, 2019
P1, N=18, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: May 2020 --> Sep 2018 | Trial primary completion date: May 2020 --> Sep 2018
- | melphalan / Generic mfg.
Trial completion: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Apr 20, 2019
P1, N=3, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed | Trial completion date: May 2020 --> Sep 2018 | Trial primary completion date: May 2020 --> Sep 2018 Suspended --> Completed
- | Immuncell-LC (GCC4002) / GC Biopharma, NN1213 / Novo Nordisk
Trial completion, Trial completion date: A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=6, Completed, Sponsor: Seoul National University Hospital
Suspended --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Oct 2018
- || Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial completion, Metastases: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2019
P1, N=26, Completed, Sponsor: Altor BioScience
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Oct 2018 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Enrollment change, Metastases: BEVACAPI: Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma (clinicaltrials.gov) - Mar 15, 2019
P=N/A, N=47, Completed, Sponsor: Centre Georges Francois Leclerc
Active, not recruiting --> Completed N=98 --> 47
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change, Trial termination, Immunomodulating, Metastases: Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma (clinicaltrials.gov) - Mar 12, 2019
P1/2, N=2, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
N=98 --> 47 N=21 --> 2 | Recruiting --> Terminated; Completion after 2 patients then stop due to end of validity of vaccine peptide
- | Davanat (galactomannan) / Galectin Therap
Enrollment change, Metastases: Peptide Vaccinations Plus GM-CT-01 in Melanoma (clinicaltrials.gov) - Mar 12, 2019
P1/2, N=6, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
N=21 --> 2 | Recruiting --> Terminated; Completion after 2 patients then stop due to end of validity of vaccine peptide N=12 --> 6
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Biological Therapy in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 9, 2019
P1, N=18, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=12 --> 6 Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Mar 6, 2019
P2, N=25, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Caprelsa (vandetanib) / Sanofi
Trial completion, Metastases: Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors (clinicaltrials.gov) - Mar 5, 2019
P1/2, N=119, Completed, Sponsor: Patrick Y. Wen, MD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | LXF821 / Novartis
Phase classification: Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma (clinicaltrials.gov) - Mar 5, 2019
P1, N=11, Terminated, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Phase classification: P=N/A --> P1
- || NanO2 (perflenapent) / NuvOx Pharma
Trial completion, Enrollment change, Trial completion date: The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (clinicaltrials.gov) - Feb 28, 2019
P1b, N=11, Completed, Sponsor: NuvOx Pharma Pty Ltd
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | N=25 --> 11 | Trial completion date: Dec 2017 --> Apr 2018
- ||| agerafenib (RXDX-105) / Roche, Daiichi Sankyo
Trial completion, Trial completion date, Metastases: Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors (clinicaltrials.gov) - Feb 27, 2019
P1, N=143, Completed, Sponsor: Ignyta, Inc.
Active, not recruiting --> Completed | N=25 --> 11 | Trial completion date: Dec 2017 --> Apr 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Feb 2019
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen
Trial completion, Trial completion date: Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance (clinicaltrials.gov) - Feb 26, 2019
P2, N=38, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Feb 2019 Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Dec 2017
- | Xalkori (crizotinib) / Pfizer
Trial completion, Trial primary completion date, Combination therapy: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Feb 26, 2019
P1, N=46, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Dec 2018
- | NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration (clinicaltrials.gov) - Feb 21, 2019
P=N/A, N=27, Terminated, Sponsor: John Wayne Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Dec 2018 N=60 --> 27 | Trial completion date: Jan 2020 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jun 2018; original PI left institute, no plan to continue using samples
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma (clinicaltrials.gov) - Feb 19, 2019
P1, N=20, Completed, Sponsor: Mayo Clinic
N=60 --> 27 | Trial completion date: Jan 2020 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jun 2018; original PI left institute, no plan to continue using samples Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme (clinicaltrials.gov) - Feb 18, 2019
P=N/A, N=102, Completed, Sponsor: Technische Universit
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Avastin (bevacizumab) / Roche
Trial termination: Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Feb 16, 2019
P2, N=41, Terminated, Sponsor: Duke University
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Study ended early due to toxicity
- | Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Enrollment change: A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Feb 12, 2019
P1/2, N=12, Terminated, Sponsor: Medical University of South Carolina
Active, not recruiting --> Terminated; Study ended early due to toxicity N=29 --> 12
- | temozolomide / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Metastases: High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma (clinicaltrials.gov) - Feb 12, 2019
P2, N=17, Completed, Sponsor: Milton S. Hershey Medical Center
N=29 --> 12 Active, not recruiting --> Completed | N=40 --> 17 | Trial completion date: Aug 2017 --> Jul 2018
- | Trial completion: Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi (clinicaltrials.gov) - Feb 8, 2019
P=N/A, N=30, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed | N=40 --> 17 | Trial completion date: Aug 2017 --> Jul 2018 Recruiting --> Completed
- | LXF821 / Novartis
Trial completion date, Trial termination, Trial primary completion date: Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma (clinicaltrials.gov) - Feb 6, 2019
P=N/A, N=11, Terminated, Sponsor: University of Pennsylvania
Recruiting --> Completed Trial completion date: Dec 2018 --> Apr 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2018; Sponsor decision to terminate prior to completion to pursue combination therapies.
- | veliparib (ABT-888) / AbbVie
Trial completion, Combination therapy: Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Feb 5, 2019
P2, N=156, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2018 --> Apr 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2018; Sponsor decision to terminate prior to completion to pursue combination therapies. Active, not recruiting --> Completed
- | buparlisib (AN2025) / Adlai Nortye
Trial completion date: Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma (clinicaltrials.gov) - Jan 30, 2019
P2, N=65, Active, not recruiting, Sponsor: Patrick Y. Wen, MD
Active, not recruiting --> Completed Trial completion date: Aug 2018 --> Jan 2019
- ||| Inlyta (axitinib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: AxiGII: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jan 24, 2019
P2, N=56, Completed, Sponsor: Bart Neyns
Trial completion date: Aug 2018 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Aug 2018
- | Trial completion, Metastases: Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients (clinicaltrials.gov) - Jan 23, 2019
P2, N=25, Completed, Sponsor: Universitair Ziekenhuis Brussel
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Aug 2018 Active, not recruiting --> Completed
- ||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial termination: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor (clinicaltrials.gov) - Jan 22, 2019
P2, N=53, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Completed --> Terminated; The applicant decided to close the study
- | Cotara (iodine I 131 derlotuximab) / Avid Bioservices
Trial completion: Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jan 19, 2019
P1, N=22, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Completed --> Terminated; The applicant decided to close the study No longer recruiting --> Completed
- ||| REC-4881 / Recursion Pharma
Trial completion, Metastases: Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Jan 19, 2019
P1, N=51, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
No longer recruiting --> Completed Active, not recruiting --> Completed
- | voruciclib (ME-522) / MEI, Zelboraf (vemurafenib) / Roche
Phase classification, Trial suspension, Metastases: Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation (clinicaltrials.gov) - Jan 19, 2019
P1, N=100, Suspended, Sponsor: Piramal Enterprises Limited
Active, not recruiting --> Completed Phase classification: P1/2 --> P1 | Recruiting --> Suspended
- Zelboraf (vemurafenib) / Roche
Trial completion, Enrollment change: Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases (clinicaltrials.gov) - Jan 19, 2019
P2, N=2, Completed, Sponsor: Yale University
Phase classification: P1/2 --> P1 | Recruiting --> Suspended Recruiting --> Completed | N=34 --> 2
- Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E (clinicaltrials.gov) - Jan 19, 2019
P2, N=31, Completed, Sponsor: Genentech, Inc.
Recruiting --> Completed | N=34 --> 2 Active, not recruiting --> Completed
- Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation (clinicaltrials.gov) - Jan 19, 2019
P2, N=2, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
- |||| Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: A Study of RO5185426 in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 19, 2019
P2, N=374, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed No Longer Available --> Completed
- | Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma (clinicaltrials.gov) - Jan 19, 2019
P1, N=15, Completed, Sponsor: Hoffmann-La Roche
No Longer Available --> Completed Active, not recruiting --> Completed
- Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 19, 2019
P1, N=7, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 19, 2019
P1, N=52, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed